Shanghai Junshi Biosciences Completes Significant H Share Placement

The latest announcement is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).

Shanghai Junshi Biosciences Co., Ltd. has successfully completed the placement of 41,000,000 new H shares under a general mandate, marking a significant milestone for the company. The placement, which represents approximately 15.75% of all issued H shares and 3.99% of all issued shares of the company, was completed on June 20, 2025, and involved independent professional and institutional investors. This strategic move is expected to enhance the company’s financial position and support its ongoing growth and development in the biopharmaceutical sector.

The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.

More about Shanghai Junshi Biosciences Co., Ltd. Class H

Shanghai Junshi Biosciences Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biosciences industry. The company focuses on the development and commercialization of innovative therapies, with a particular emphasis on biopharmaceutical products.

Average Trading Volume: 5,791,608

Technical Sentiment Signal: Buy

Current Market Cap: HK$33.7B

For an in-depth examination of 1877 stock, go to TipRanks’ Overview page.